Journal
EXPERT OPINION ON DRUG SAFETY
Volume 12, Issue 1, Pages 65-79Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1517/14740338.2013.741585
Keywords
fibrate; glitazone; PPAR; T2DM; TZD
Categories
Funding
- F. Hoffmann-La Roche Ltd.
Ask authors/readers for more resources
Introduction: The peroxisome proliferator-activated receptor (PPAR)-alpha and -gamma agonists, fibrates and glitazones, are effective treatments for dyslipidemia and type 2 diabetes mellitus, respectively, but exhibit class-related, as well as compound-specific safety characteristics. Areas covered: This article reviews the profiles of PPAR-alpha, PPAR-gamma, and dual PPAR-alpha/gamma agonists with regard to class-related and compound-specific efficacy and adverse effects. We explore how learnings from first-generation drugs are being applied to develop safer PPAR-targeted therapies. Expert opinion: The finding that rosiglitazone may increase risk for cardiovascular events has led to regulatory guidelines requiring demonstration of cardiovascular safety in appropriate outcome trials for new type 2 diabetes mellitus drugs. The emerging data on the possibly increased risk of bladder cancer with pioglitazone may prompt the need for post-approval safety studies for new drugs. Since PPAR-alpha and -gamma affect key cardiometabolic risk factors (diabetic dyslipidemia, insulin resistance, hyperglycemia, and inflammation) in a complementary fashion, combining their benefits has emerged as a particularly attractive option. New PPAR-targeted therapies that balance the relative potency and/or activity toward PPAR-alpha and -gamma have shown promise in retaining efficacy while reducing potential side effects.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available